APLS
Apellis Pharmaceuticals Inc
3.40$
-0.1%
vs. previous close
Closing price · As of: Aug 13, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +166.9% | -28.1% | +563.9% | +11.8% | +91.2% | +146.8% | -8.2% | -13.8% | +3.8% | +12.2% | +21.5% | |
| – | +167.0% | -28.1% | +565.0% | +11.2% | +84.3% | +145.8% | -10.2% | -12.7% | +6.5% | +3.0% | +28.6% | |
| – | +164.3% | -30.9% | +606.4% | +0.4% | +99.7% | +60.7% | +13.2% | -13.8% | -36.4% | +17.1% | +13.7% | |
| – | +164.3% | -30.9% | +606.4% | +0.4% | +99.7% | +149.3% | -20.1% | -21.3% | -36.2% | +18.1% | +12.4% | |
| – | +277.1% | -23.3% | -3.7% | +13.6% | – | – | +220.4% | -90.4% | +2,571.7% | +31.6% | +34.8% | |
| – | – | – | – | – | – | – | +2,400,299,900.0% | +257.1% | +70.8% | -43.6% | +72.8% | |
| – | – | – | – | – | +1,512.1% | +55.5% | +6.3% | -4.5% | – | – | – | |
| – | +195.9% | +13.7% | +812.0% | +28.2% | +734.1% | +113.0% | -9.6% | -13.6% | +0.7% | +10.5% | +7.4% | |
| – | +195.9% | +13.7% | +80.1% | +159.8% | +286.2% | +95.2% | +2.7% | +27.1% | +47.7% | -25.1% | +74.4% | |
| – | – | – | – | -93.7% | +56.6% | +41.2% | +11.7% | +36.7% | +14.5% | +4.8% | +1,391.9% | |
| – | +229.7% | +2.8% | +43.8% | +179.9% | -18.5% | +1.4% | +99.5% | +120.8% | +0.5% | +2.8% | +47.3% | |
| – | – | – | – | -3.8% | +461.8% | +151.7% | -47.3% | -50.9% | +0.3% | +386.7% | -20.1% | |
| – | +164.5% | -32.0% | +526.0% | +8.1% | -78.7% | +497.6% | -2.9% | -14.5% | +14.5% | +17.5% | +62.0% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +0.0% | +0.0% | -23.3% | +292.2% | +14.4% | +20.8% | +12.3% | +25.7% | +11.8% | +4.4% | +1.7% |
Data as of: August 13, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.